Bailard Inc. Has $339,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

Bailard Inc. boosted its holdings in Agilent Technologies, Inc. (NYSE:A) by 4.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,613 shares of the medical research company’s stock after buying an additional 111 shares during the period. Bailard Inc.’s holdings in Agilent Technologies were worth $339,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Livelsberger Financial Advisory acquired a new stake in Agilent Technologies during the fourth quarter worth $26,000. VisionPoint Advisory Group LLC bought a new stake in shares of Agilent Technologies in the 4th quarter valued at approximately $29,000. Rise Advisors LLC raised its holdings in shares of Agilent Technologies by 527.8% in the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after buying an additional 190 shares in the last quarter. YHB Investment Advisors Inc. acquired a new stake in Agilent Technologies in the 1st quarter valued at $34,000. Finally, Riverview Trust Co acquired a new position in Agilent Technologies during the first quarter worth $41,000. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $140.00, for a total value of $274,120.00. Following the completion of the sale, the chief executive officer now owns 26,076 shares in the company, valued at $3,650,640. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,874 shares of company stock valued at $2,811,770. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. UBS Group boosted their target price on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. TD Cowen raised their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Bank of America upped their target price on shares of Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Jefferies Financial Group reaffirmed a “hold” rating and set a $135.00 price objective (down previously from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. Finally, Evercore ISI boosted their target price on Agilent Technologies from $130.00 to $135.00 and gave the stock an “in-line” rating in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $140.80.

Agilent Technologies Stock Performance

NYSE:A opened at $140.50 on Tuesday. The company has a market cap of $40.99 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 4.86 and a beta of 1.05. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.35. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. The stock has a fifty day moving average price of $134.34 and a 200-day moving average price of $138.65.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.43 earnings per share. As a group, equities analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.